DefiniGEN strengthens Board with appointment of Professor Sir John Savill
DefiniGEN, the world leader in human iPSC differentiation and disease modelling, announces the appointment of Professor Sir John Savill as a Non-Executive Director of the Board.
Sir John will bring his expertise in translational science to DefiniGEN enabling the company to accelerate the development of new products and services which can improve the efficiency and economics of drug development.
Sir John Savill was previously the Chief Executive of the Medical Research Council (MRC) in the UK. Within this role he was responsible to UK Parliament for expenditure of approximately £800 million per year as MRC’s Accounting Officer. Alongside the MRC role, Savill was also Vice-Principal and Head of the College of Medicine at the University of Edinburgh. As a renowned expert in research and innovation, Sir John will aid DefiniGEN in further developing its partnerships with the pharmaceutical and biomedical communities.
Dr Marcus Yeo, Chief Executive Officer, commented: “I am delighted to welcome John to the DefiniGEN board. With his extensive experience as a highly-regarded clinician and scientist I am confident that John will prove to be highly valuable as DefiniGEN continues to grow internationally in key markets.”
Sir John Savill stated: “DefiniGEN is one of the UK’s most innovative translational science companies providing valuable tools for biomedical research. I’m delighted to join the board at this important stage in the company’s development.”
DefiniGEN provides human liver cells for preclinical drug development and disease modelling applications using human Induced Pluripotent Stem Cell hIPSC technology.